CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
S1318 SWOG A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone; Vincristine; Methotrexate; 6-Mercaptopurine) for Patients >= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517); Prednisone and Blinatumomab for Patients >= 65 Years Of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL; and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF) Adult CIRB - Early Phase Emphasis
S1320 SWOG A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma Adult CIRB - Early Phase Emphasis
S1400 SWOG A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) Adult CIRB - Late Phase Emphasis
S1403 SWOG A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124) Adult CIRB - Late Phase Emphasis
S1404 SWOG A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Adult CIRB - Late Phase Emphasis
S1406 SWOG Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Adult CIRB - Early Phase Emphasis
S1416 SWOG Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Brain Metastases Adult CIRB - Late Phase Emphasis
S1418 SWOG A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy Adult CIRB - Late Phase Emphasis
S1500 SWOG A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) Adult CIRB - Late Phase Emphasis
S1501 SWOG Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer; Phase III Cancer Prevention and Control CIRB